Novo Holdings, the guardian firm of Novo Nordisk, can proceed with its deliberate $16.5 billion acquisition of Catalent, a number one contract drug producer, after U.S. regulators declined to problem the deal following months of scrutiny.
The businesses anticipate to shut the transaction within the subsequent a number of days, after a deadline handed for the U.S. Federal Commerce Fee to lift objections and different regulatory situations had been fulfilled, in keeping with statements issued by Novo Nordisk and Catalent. We requested the FTC for remark and can replace you accordingly. Final week, the European Fee authorized the transaction.
The deal had generated monumental curiosity over issues that competitors within the pharmaceutical business may very well be harmed. Certainly, the transfer was prompted by sporadic shortages of one of many world’s hottest-selling drugs — Novo Nordisk’s weight reduction therapy Wegovy — and designed, partially, to resolve what has been a crucial and seemingly intractable drawback for Novo Nordisk.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
